CClinicalTrials.gg
Not yet recruitingNCT06759480Updated Jan 6, 2025

Study of Laparoscopic Radical Hysterectomy Based on Space Anatomy in Patients With IB3 and IIA2 Cervical Cancer

An observational study in Locally Advanced Cervical Cancer, sponsored by International Peace Maternity and Child Health Hospital. Not yet recruiting. Open to female participants aged 20 Years to 70 Years. Per ClinicalTrials.gov, last updated 2025-01-06.

Sponsored by International Peace Maternity and Child Health Hospital · Observational

From the registry’s dates

  • Primary completion was expected by Jan 2025, 1 year 8 months ago, but the record still lists the study as not yet recruiting.
Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
500
Ages
20 Years to 70 Years
Sex
Female
01

Study summary

Radical hysterectomy is an effect treatment for FIGO IB3 and IIA2 cervical cancer patients who refuse to receive radical concurrent chemoradiotherapy. However, due to the large tumor size, both patients and surgeons encountered the risk of substantial bleeding, urinary tract damage, and unsatisfactory resection during surgery. Therefore, the exploration of effective and safe surgical treatments is crucial in enhancing the quality of life and prognosis for patients. Laparoscopic radical hysterectomy (LRH) offers the advantages of reduced bleeding and accelerated recovery, thereby minimizing patient discomfort and enhancing their quality of life. However, the prognosis of patients who received LRH or traditional abdominal radical hysterectomy (ARH) remains controversial. We proposed a modified LRH skill based on new space anatomy concept. In our previous single-center study, the result demonstrates that LRH based on space anatomy leads to less intraoperative blood loss and decreased ureteral injury rate compared with traditional skill. The benefits of this new method for patient survival remain uncertain. In this multicenter retrospective study, we aim to assess clinical prognosis and safety of this new LRH compared with traditional abdominal radical hysterectomy (ARH) in FIGO IB3 and IIA2 cervical cancer.

02

Conditions studied

  • Locally Advanced Cervical Cancer
03

In context

Uterine Cervical Neoplasms

1,881 studies on the registry are indexed under Uterine Cervical Neoplasms; 567 are open to participants now.

This study's planned enrollment of 500 is above the median of 220 across 419 observational studies indexed under Uterine Cervical Neoplasms.

Browse Uterine Cervical Neoplasms studies →

Lead sponsor

International Peace Maternity and Child Health Hospital is the lead sponsor of 14 studies on the registry; 6 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years to 70 Years
Sexes eligible
Female
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients who clinically diagnosed with IB3 and IIA2 cervical cancer are retrospectively collected from electronic medical records of four tertiary medical center from January 2012 to January 2022

Inclusion criteria

  1. Aged between 20 to 70 years
  2. Preoperative clinical diagnosis was FIGO 2018 stage IB3 or IIA2 cervical cancer;
  3. Patients who received standard Querleu-Morrow type C radical hysterectomy (including ARH or LRH based on space anatomy) and pelvic lymphadenectomy;
  4. no preoperative suspected lymph nodes metastasis, parametrial involvement or lower 1/3 vagina involvement.

Exclusion criteria

Exclusion Criteria:

  1. patients who had active double cancer or uncontrolled serious concurrent disease that might compromise prognosis;
  2. pregnancy;
  3. incomplete radical surgery;
  4. follow-up time less than 6 months or lost to follow-up
05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
500 participants (estimated)
Patient registry
No

Groups and cohorts

  • LRH group

    In this group, patients received a modified laparoscopic radical hysterectomy(LRH) based on space antomy.

    Procedure: Laparoscopic radical hysterectomy based on space anatomy

  • ARH group

    In this group, patients received a traditional abdominal radical hysterectomy(ARH). ARH group is defined as a control group.

    Procedure: Abdominal radical hysterectomy

Interventions

  • ProcedureLaparoscopic radical hysterectomy based on space anatomy

    This is a modified laparoscopic radical hysterectomy based on space anatomy. By identifying the vesicouterine ligament and four associated special spaces, the ureter can be completely liberated from the external aspect of the uterus. This skill not only reduces rate of surgical complications but also facilitates optimal tumor resection.

  • ProcedureAbdominal radical hysterectomy

    This producre is a classic and traditional radical hysterectomy.

06

What researchers measure

Primary outcomes

  1. Overall survival

    The time from end of surgery to death from any cause.

    Time frame: 5 years

  2. Progression-free survival

    The time from end of surgery to either the first documented disease progression or death from any cause.

    Time frame: 5 years

Secondary outcomes

  1. Surgery complication rate

    Including the rates of ureter or bladder injury, colon injury, deep vein thrombosis event and infection.

    Time frame: Intraoperative or within 2 weeks after surgery

  2. Intraoperative blood loss

    Time frame: Intraoperative blood loss

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jan 6, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06759480
Lead sponsor
International Peace Maternity and Child Health Hospital
Responsible party
Sponsor
First posted
Jan 6, 2025
Start date
Dec 27, 2024 (estimated)
Primary completion
Jan 15, 2025 (estimated)
Completion
Mar 15, 2025 (estimated)
Last update
Jan 6, 2025

Study contacts

Sibang Chen
Contact
sibang_chen@163.com
+86 18721757863

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Dec 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion